We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Xi'an Tianlong Science & Technology Co., Ltd

Tianlong is an innovative, high-technology company that provides professional PCR detection devices, reagent kits and... read more Featured Products: More products

Download Mobile App




Tianlong Showcases Latest Real-Time PCR System and Innovative Molecular Diagnostic Solutions at MEDICA 2023

By LabMedica International staff writers
Posted on 29 Nov 2023
Print article
Image: TianLong Science and Technology Co., Ltd. is showcasing its cutting-edge products and innovative molecular diagnostic solutions at MEDICA 2023 (Photo courtesy of TianLong)
Image: TianLong Science and Technology Co., Ltd. is showcasing its cutting-edge products and innovative molecular diagnostic solutions at MEDICA 2023 (Photo courtesy of TianLong)
TianLong Science and Technology Co., Ltd. (Shaanxi, China) is showcasing its cutting-edge products and innovative molecular diagnostic solutions at MEDICA 2023.

MEDICA in Düsseldorf, a leading medical B2B trade fair, has once again become a global highlight from 13-16 November this year. Tianlong Technology made its appearance at this grand event, in collaboration with Kehua Bio-engineering, showcasing the latest IVD solutions to the global market.

TianLong participated in MEDICA 2023 with excellent products and solutions including iGeneCase 1600 Diagnostics-in-a-Suitcase, Panall 8000 all-in-one molecular diagnosis system, and PANA 9600X Automated Nucleic Acid Workstation, as well as a variety of nucleic acid extraction systems and PCR systems, supporting lab detection in automation, informatics, and intelligence.

The nucleic acid extraction and PCR testing reagents cover the detection of various common diseases, meeting the detection needs in clinical diagnosis, epidemic monitoring, food safety, forensic identification, scientific research, etc.

During the event, Tianlong engaged in insights exchanges and cooperative discussions with experts, scholars, as well as companies from around the world, and also presented visitors with pioneering technologies and innovative products, as well as the latest research achievements and application cases in molecular diagnostics.

Thanks to the participation in MEDICA 2023, Tianlong has gained valuable experience and feedback, enhanced market influence, and expanded international cooperation opportunities. In the future, Tianlong will continue to develop research and development efforts and innovations in the medical industry.

Gold Member
Troponin T QC
Troponin T Quality Control
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
PAPP-A Test
PAPP-A Mass Units AccuBind ELISA
New
Microplates
Eppendorf Microplates

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.